Citigroup Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $33.00

Hims & Hers Health (NYSE:HIMS) had its price objective cut by Citigroup from $35.00 to $33.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities research analysts also recently commented on the stock. JPMorgan Chase & Co. cut their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Bank of America lifted their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday. UBS Group set a $23.00 price objective on Hims & Hers Health in a research report on Friday, May 22nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average price target of $32.43.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $28.79 on Tuesday. The firm’s 50-day moving average price is $32.07 and its 200-day moving average price is $26.08. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market cap of $6.66 billion, a PE ratio of -45.70, a PEG ratio of 57.49 and a beta of 2.40. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 5.89%. The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same period in the previous year, the firm earned $0.17 earnings per share. The firm’s revenue for the quarter was up 38.2% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health will post -0.05 EPS for the current year.

Insiders Place Their Bets

In other news, insider Irene Becklund sold 7,573 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25. Following the completion of the sale, the insider owned 11,280 shares of the company’s stock, valued at $341,220. The trade was a 40.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the sale, the insider owned 181,861 shares of the company’s stock, valued at $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 83,126 shares of company stock valued at $2,711,339. 11.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new stake in Hims & Hers Health during the second quarter valued at about $46,220,000. Handelsbanken Fonder AB raised its stake in shares of Hims & Hers Health by 4.0% in the second quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after buying an additional 2,300 shares during the period. Valeo Financial Advisors LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $225,000. FNY Investment Advisers LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $347,000. Finally, GAMMA Investing LLC grew its stake in shares of Hims & Hers Health by 32.0% during the 2nd quarter. GAMMA Investing LLC now owns 4,654 shares of the company’s stock valued at $161,000 after acquiring an additional 1,128 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers reported second-quarter revenue of $753.2 million, up 38.2% year over year and ahead of analyst expectations of $698.9 million. Subscriber growth and demand for its health and weight-management offerings remain key growth drivers. Hims & Hers Health Q2 2026 Earnings Call Summary
• Positive Sentiment: The company raised its annual revenue outlook, supporting the long-term growth case. Needham and Bank of America analysts reportedly maintained a more constructive view, suggesting the stock could appreciate as investments in new products and international expansion begin to pay off. Needham analyst outlook
• Neutral Sentiment: Hims plans to introduce certain legally available peptide products in 2026. However, analysts expect the launch to contribute little revenue this year, making it primarily a longer-term growth opportunity. As Hims prepares for peptides launch, Wall Street cautious on prospects this year
• Negative Sentiment: Quarterly EPS came in at a loss of $0.37, substantially below the expected loss of $0.05. The wider loss was linked to the shift toward branded GLP-1 obesity drugs, while gross-margin compression and negative free cash flow raised concerns that faster growth is not translating into improved earnings. Hims & Hers’ Revenue Beat Came With a Profitability Problem
• Negative Sentiment: Citigroup issued a pessimistic outlook, reflecting skepticism about near-term margins and execution. Citigroup forecast
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and alleged fiduciary-duty issues. The inquiries follow an FTC lawsuit concerning alleged data-sharing, billing and cancellation practices, adding legal, reputational and potential financial risks. HIMS shareholder alert

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.